Truist Financial Maintains Buy Rating for PTC Therapeutics (PTCT)

Truist Financial analyst Joon Lee maintains a Buy rating on PTC Therapeutics (PTCT). Lee, a 5-star analyst, has an average return of 22.0% and a 52.38% success rate. Other analysts have also provided ratings for PTCT, including a Buy from Morgan Stanley's Judah Frommer and a Hold from TD Cowen. The company has a one-year high of $58.38 and a one-year low of $30.41, with an average volume of 1.18M. Corporate insider sentiment is negative, with 47 insiders selling their shares over the past quarter.

PTC Therapeutics Inc. (NASDAQ: PTCT) has seen its stock price surge following the FDA approval of Sephience, a specialized treatment for phenylketonuria (PKU). The approval has bolstered investor confidence and underscored the company's strong financial performance and strategic initiatives.

The company reported revenues of $179 million in Q2 2025, surpassing previous projections and earnings per share of $0.83, a notable improvement over expected $1.06 [1]. The launch of Sephience has been well-received by the market, with analysts maintaining a positive outlook despite slight adjustments to target prices [1].

PTC Therapeutics boasts a substantial cash reserve of nearly $2 billion, positioning it well against market volatility and opening doors for future expansion [1]. The company's strong financial performance and strategic initiatives, including the launch of Sephience and the ongoing performance of Translarna, position it well for future growth.

However, analysts have mixed sentiments. William Blair has cut its FY2025 earnings estimate for PTC Therapeutics from $6.46 to $6.40 per share [2]. Other analysts, such as Morgan Stanley's Judah Frommer, maintain a Buy rating, while TD Cowen has issued a Hold rating. The company's stock price has shown a bullish trend, opening at $48.98 and climbing above $54, settling around $51.88 [1].

Despite the positive market reaction, corporate insider sentiment is negative, with 47 insiders selling their shares over the past quarter [2]. Truist Financial analyst Joon Lee maintains a Buy rating on PTC Therapeutics, with an average return of 22.0% and a 52.38% success rate [2].

References:
[1] https://stockstotrade.com/news/ptc-therapeutics-inc-ptct-news-2025_08_19/
[2] https://www.marketbeat.com/instant-alerts/william-blair-cuts-earnings-estimates-for-ptc-therapeutics-2025-08-21/